<DOC>
	<DOCNO>NCT00294736</DOCNO>
	<brief_summary>This multicenter , open-label , randomized phase 1 study escalate dos Tarceva patient advance NSCLC currently smoke . Part I establish maximum tolerate dose ( MTD ) Tarceva current smoker . In Part II , patient randomize 1:1 two treatment group : Arm A ( Tarceva MTD establish Part I ) Arm B ( 150 mg Tarceva daily ) . Patients arm treat two week pharmacokinetic sample collect day 14 . Part II open Nov-2006 .</brief_summary>
	<brief_title>A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study Tarceva Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue Smoke After Failure One Two Prior Chemotherapy Regimens</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis stage IIIB/IV NSCLC ; Must receive 1 2 prior chemotherapy regimen advance NSCLC progressive disease ; Must recover treatmentrelated toxicity prior registration , except alopecia , grade 1 fatigue , grade 1 neurotoxicity ; A current cigarette smoker ( minimum 10 cigarette per day &gt; = 1 year positive test cotinine ) despite advice support quit ; Age &gt; = 18 year ; ECOG PS 01 predict life expectancy &gt; = 12 week ; Previous surgery permit provide wound healing occur prior registration ; Adequate hematopoietic , hepatic renal function define follow : ANC &gt; = 1.5 x 10^9/L , platelet &gt; = 100 x 10^9/L , bilirubin &lt; = 1.5 x ULN , ALT &lt; = 2.5 x ULN ( 5 x ULN case liver metastasis ) , creatinine &lt; = 1.5 x ULN ; No prior treatment Tarceva gefitinib ( drug significant activity EGFR ( eg , cetuximab and/or ZD6474 ) ) ; Patients reproductive potential must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test within 14 day prior registration ; Accessible repeat dose followup . Any concurrent anticancer cytostatic cytotoxic chemotherapy ; Concomitant CYP3A4 CYP1A2 inducers/inhibitors ( 14 day prior study ) exception tobacco ; Other active malignancy , unless diseasefree without cancerspecific therapy least last 5 year . Basal squamous cell skin cancer exclude ; Significant history cardiac disease unless disease wellcontrolled ; Active uncontrolled infection serious illness medical condition could interfere patient 's ongoing participation study ; History psychiatric condition might impair patient 's ability understand comply requirement ; study provide informed consent . Gastrointestinal abnormality , include inability take oral medication , requirement IV alimentation , active peptic ulcer prior surgical procedure affect absorption ; Clinically significant ophthalmologic abnormality ; Pregnant breastfeeding female . Males females practice effective birth control ; Symptomatic brain metastasis stable , require steroid , require radiation within last 28 day ; History allergic reaction attribute compound similar chemical biologic composition study drug ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>smoker</keyword>
</DOC>